We are live on
!
Find out more
MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter
Est. Return
+16.24%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$15.9M
AUM Growth
-$203M
(-93%)
Cap. Flow
-$209M
Cap. Flow
% of AUM
-1,312.38%
Top 10 Holdings %
Top 10 Hldgs %
77.88%
Holding
26
New
3
Increased
–
Reduced
12
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
THOR
THORATEC CORPORATION
THOR
|
+$945K |
| 2 |
Labcorp
LH
|
+$687K |
| 3 |
Cencora
COR
|
+$676K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$15.9M |
| 2 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$15.6M |
| 3 |
DexCom
DXCM
|
+$15.2M |
| 4 |
Amgen
AMGN
|
+$12.8M |
| 5 |
Universal Health Services
UHS
|
+$11.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.48% |
| 2 | Miscellaneous | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$21.6B
| $1.86M | 11.72% |
10,808
-104,269
| -91% | -$15.9M |
|
|
2
Universal Health Services
UHS
$10.2B
| $1.82M | 11.44% |
15,453
-107,451
| -87% | -$11.9M |
|
|
CYNO
3
DELISTED
Cynosure, Inc. Class A
CYNO
| $1.34M | 8.43% |
43,729
-271,988
| -86% | -$8.21M |
|
4
Humana
HUM
$48.9B
| $1.14M | 7.17% |
6,403
-55,178
| -90% | -$8.73M |
|
|
MNK
5
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $1.08M | 6.8% |
8,540
-136,531
| -94% | -$15.6M |
|
6
Regeneron Pharmaceuticals
REGN
$81.7B
| $1.08M | 6.79% |
2,392
-27,228
| -92% | -$11.5M |
|
|
THOR
7
DELISTED
THORATEC CORPORATION
THOR
| $1.04M | 6.52% |
+24,765
| New | +$945K |
|
8
Eli Lilly
LLY
$1.01T
| $1.03M | 6.48% |
14,192
-141,225
| -91% | -$10.1M |
|
|
9
DexCom
DXCM
$32B
| $1.02M | 6.4% |
65,328
-1,002,976
| -94% | -$15.2M |
|
|
MDCO
10
DELISTED
Medicines Co
MDCO
| $974K | 6.12% |
34,744
-401,242
| -92% | -$11.3M |
|
|
11
Cencora
COR
$62.3B
| $764K | 4.8% |
+6,717
| New | +$676K |
|
|
12
Labcorp
LH
$25.6B
| $723K | 4.55% |
+6,676
| New | +$687K |
|
13
Incyte
INCY
$24.8B
| $710K | 4.46% |
7,742
-41,475
| -84% | -$3.43M |
|
14
Zoetis
ZTS
$30.4B
| $683K | 4.29% |
14,747
-91,075
| -86% | -$4.11M |
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals
ALXN
| $638K | 4.01% |
3,680
-62,280
| -94% | -$11.3M |
|
16
Align Technology
ALGN
$10.9B
| – | – |
-196,368
| Closed | -$11M |
|
|
17
Amgen
AMGN
$206B
| – | – |
-80,600
| Closed | -$12.8M |
|
|
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
| – | – |
-394,897
| Closed | -$6.76M |
|
19
Encompass Health
EHC
$12.1B
| – | – |
-135,611
| Closed | -$4.15M |
|
|
SEM
20
DELISTED
Select Medical
SEM
| – | – |
-1,008,652
| Closed | -$7.83M |
|
21
West Pharmaceutical
WST
$25B
| – | – |
-210,910
| Closed | -$11.2M |
|
|
AMAG
22
DELISTED
AMAG Pharmaceuticals
AMAG
| – | – |
-113,079
| Closed | -$4.82M |
|
|
WCG
23
DELISTED
Wellcare Health Plans, Inc.
WCG
| – | – |
-117,823
| Closed | -$9.67M |
|
|
ENZY
24
DELISTED
Enzymotec Ltd
ENZY
| – | – |
-681,778
| Closed | -$5.13M |
|
|
UAM
25
CALL
DELISTED
Universal American Corp
UAM
| – | – |
-500,000
| Closed | -$4.64M |
|
Similar funds
IC
PA
GMIM
JHWCP
SMPIAI
NCMG
CAD
GPI
March Altus Capital Management's Q1 2015 Portfolio in Review
As of Q1 2015, March Altus Capital Management held 26 positions worth $15.9M, down 93% from $219M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
March Altus Capital Management withdrew a net $209M in Q1 2015, closing 11 positions and reducing 12 holdings. Its most notable exit was Amgen, an estimated $12.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 98% a quarter earlier, followed by Miscellaneous.
Against the trend, March Altus Capital Management opened a new position in THORATEC CORPORATION worth $1.04M.
- March Altus Capital Management's largest Q1 2015 buy was THORATEC CORPORATION: 24,765 shares worth $1.04M.
- March Altus Capital Management's biggest Q1 2015 reduction was United Therapeutics, cutting an estimated $15.9M.
- March Altus Capital Management fully exited Amgen in Q1 2015, selling an estimated $12.8M.
- March Altus Capital Management's ten largest holdings make up 78% of its $15.9M portfolio in Q1 2015.
- March Altus Capital Management opened 3 new positions and closed 11 in Q1 2015.
- March Altus Capital Management's portfolio value fell 93% quarter-over-quarter to $15.9M.
Based on March Altus Capital Management's 13F filing for Q1 2015, filed 15 May 2015.